Table 2 Use of treatments among respondents overall and stratified by mean monthly migraine days (MMDs)
|  | Overall | 4 ≤ MMD < 8 | 8 ≤ MMD < 15 | MMD ≥ 15 | p-value |
|---|---|---|---|---|---|
N | 338 | 133 | 139 | 66 | Â |
Use of acute treatment (%) | 319 (94.4) | 128 (96.2) | 129 (92.8) | 62 (93.9) | 0.455 |
Currently used acute medication (%) | |||||
 Non-opioid pain relievers | 254 (80.4) | 101 (78.9) | 109 (85.8) | 44 (72.1) | 0.074 |
 Triptans | 256 (81.0) | 98 (76.6) | 106 (83.5) | 52 (85.2) | 0.240 |
 Anti-emetics | 112 (35.4) | 41 (32.0) | 43 (33.9) | 28 (45.9) | 0.157 |
 Any other | 70 (22.2) | 23 (18.0) | 25 (19.7) | 22 (36.1) | 0.014 |
Currently used acute treatment (%) | |||||
 Medicine prescribed by a doctor | 311 (97.5) | 126 (98.4) | 125 (96.9) | 60 (96.8) | 0.717 |
 OTC medicine | 138 (43.3) | 55 (43.0) | 60 (46.5) | 23 (37.1) | 0.468 |
 Non-medical complementary therapies* | 95 (29.8) | 37 (28.9) | 41 (31.8) | 17 (27.4) | 0.795 |
 Any other | 45 (14.1) | 15 (11.7) | 22 (17.1) | 8 (12.9) | 0.449 |
Ever received prophylactic prescription (%) | 281 (83.1) | 103 (77.4) | 116 (83.5) | 62 (93.9) | 0.010 |
Currently used prophylactic medications (%) | |||||
 Beta-blockers | 121 (43.1) | 49 (47.6) | 49 (42.2) | 23 (37.1) | 0.409 |
 Anti-epileptics | 97 (34.5) | 29 (28.2) | 47 (40.5) | 21 (33.9) | 0.157 |
 Anti-depressants | 56 (19.9) | 17 (16.5) | 24 (20.7) | 15 (24.2) | 0.471 |
 Onabotulinum toxin A | 43 (15.3) | 4 (3.9) | 17 (14.7) | 22 (35.5) | < 0.001 |
 Any other | 78 (27.8) | 29 (28.2) | 32 (27.6) | 17 (27.4) | 0.993 |
Number of prophylactic treatment switches/failures (%) | |||||
 Never | 63 (22.4) | 37 (35.9) | 18 (15.5) | 8 (12.9) | < 0.001 |
 Once | 21 (7.5) | 12 (11.7) | 5 (4.3) | 4 (6.5) | |
 Twice | 29 (10.3) | 15 (14.6) | 10 (8.6) | 4 (6.5) | |
 3 times | 47 (16.7) | 13 (12.6) | 29 (25.0) | 5 (8.1) | |
 4 times | 25 (8.9) | 8 (7.8) | 9 (7.8) | 8 (12.9) | |
 5 times | 20 (7.1) | 4 (3.9) | 11 (9.5) | 5 (8.1) | |
 6 times or more | 76 (27.0) | 14 (13.6) | 34 (29.3) | 28 (45.2) | |